NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 09 09:34AM ET
23.14
Dollar change
+0.39
Percentage change
1.71
%
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y-10.29% Total Holdings45 Perf Week2.80%
SponsorTema ETF Type Tagsequity Return% 3Y- AUM10.00M Perf Month3.44%
Fund Family Bond Type Tagshealthcare Return% 5Y- NAV/sh Perf Quarter-7.09%
Index- Average Maturity Tags- Return% 10Y 52W High27.39 -15.51% Perf Half Y-5.45%
Index Weighting Commodity Type Tags- Return% SI 52W Low19.86 16.51% Perf YTD-5.40%
Active/Passive Quant Type Tags- Flows% 1M0.00% Volatility0.00% 0.30% Perf Year-6.36%
Dividend TTM0.00 (0.01%) ESG Type Tags- Flows% 3M0.00% ATR (14)0.30 Perf 3Y-
Dividend Ex-DateDec 11, 2024 Dividend Type Sector/Theme Flows% YTD0.00% RSI (14)57.73 Perf 5Y-
Dividend Gr. 3/5Y- - Structure Type Region Flows% 1Y Beta0.74 Perf 10Y-
Expense0.75% Growth/Value SMA202.62% Flows% 3Y Rel Volume0.02 Prev Close22.75
Inverse/Leveraged Market Cap SMA503.05% Flows% 5Y Avg Volume0.60K Price23.14
IPOJan 23, 2024 Option/ShortNo / Yes SMA200-6.95% Trades Volume5 Change1.71%
Tema Neuroscience And Mental Health ETF seeks to provide long-term growth of capital. Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.